ArticleEJNMMI research2023
[
Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Neuroimaging evidence for a dopamine-independent association between motor cortex microstructure and Parkinson's disease severity.NPJ Parkinson's disease · 2026Article
- Molecular neuroimaging of Parkinson's disease: association of motor and non-motor symptoms with synaptic density, dopaminergic and serotonergic systems.Neuroimage. Reports · 2026Article
- Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual-Tracer Positron Emission Tomography Imaging Study.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Smartphone-based prediction of dopaminergic deficit in prodromal and manifest Parkinson's disease.NPJ digital medicine · 2025Article
- C18:0 GM3 ganglioside's efficacy in LPS-induced parkinsonism: neuroprotection, inflammatory inhibition and gliosis mitigation.Behavioral and brain functions : BBF · 2025Article
- [PCN reports : psychiatry and clinical neurosciences · 2025Article
- Longitudinal Assessment of Parkinson's Motor Symptoms and Dopaminergic Dysfunction Patterns Using DaTSCAN.Clinical parkinsonism & related disorders · 2025Article
- Mapping the distribution of neurotransmitters to resting-state functional connectivity in Parkinson's disease.Brain communications · 2025Article
- Parkinson's Disease: Biomarkers for Diagnosis and Disease Progression.International journal of molecular sciences · 2024Review
- Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [Brain communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorrelations between dopamine transporter (DAT) availability and Parkinson's disease (PD) motor symptoms vary depending on the imaging modality, choice of regions of interest and clinical measures. We aimed to validate the PET radioligand [
methodsWe included 41 PD patients (age 45-79 years; H&Y stage < 3) and 37 healthy control subjects in a cross-sectional study with dynamic [
resultsWe found negative correlations (p < 0.02) between symptom duration and BP
conclusionResults are in agreement with earlier findings in in vivo and post-mortem studies and validate [
trial registrationEudraCT 2011-0020050, Registered April 26 2011; EudraCT 2017-003327-29, Registered October 08 2017; EudraCT 2017-001585-19, Registered August 2 2017. https://eudract.ema.europa.eu/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.